Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2650 - Correlation between SPARC expression and efficacy of nab-paclitaxel for advanced gastric cancer refractory to fluoropyrimidine: an exploratory analysis of a phase II trial, CCOG1303

Date

09 Sep 2017

Session

Poster display session

Presenters

Daisuke Kobayashi

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

D. Kobayashi1, A. Enomoto2, Y. Mochizuki3, T. Matsui4, H. Nakayama5, Y. Kawase6, K. Ishigure7, T. Shikano8, K. Torii9, Y. Kodera1

Author affiliations

  • 1 Gastroenterological Surgery, Nagoya University, Graduate School of Medicine, 466-8550 - Nagoya/JP
  • 2 Pathology, Nagoya University, Graduate School of Medicine, 466-8550 - Nagoya/JP
  • 3 Department Of Surgery, Komaki Municipal Hospital, 4858520 - Komaki/JP
  • 4 Department Of Surgery, Aichi Cancer Center Hospital, Okazaki/JP
  • 5 Department Of Surgery, National Hospital Organization Nagoya Medical Center, Nagoya/JP
  • 6 Department Of Surgery, Tosei General Hospital, Seto/JP
  • 7 Department Of Surgery, Konan Kosei Hospital, Konan/JP
  • 8 Department Of Surgery, Yokkaichi Municipal Hospital, Yokkaichi/JP
  • 9 Department Of Surgery, Nakatsugawa Municipal General Hospital, Nakatsugawa/JP
More

Resources

Abstract 2650

Background

Secreted protein acidic and rich in cysteine (SPARC) reportedly influences the response to albumin-bound paclitaxel due to its characteristics of albumin-binding matrix-associated protein that may enhance the drug accumulation in the tumor tissue. However, its role in gastric cancer (GC) has been controversial. In this study, correlation between SPARC expression and the efficacy of nab-paclitaxel (nab-PTX) for GC was evaluated to explore its potential as a predictor of sensitivity.

Methods

In a multi-institutional prospective phase II trial (CCOG1303), efficacy of nab-PTX under a modified dose reduction criteria was evaluated in 47 advanced GC patients refractory to fluoropyrimidine. Correlation between SPARC expression on immunohistochemistry and efficacy endpoints was evaluated as a predetermined exploratory analysis in the CCOG1303 trial. SPARC staining was scored in two compartments: cancer associated fibroblasts (CAF) in the tumor stroma and tumor epithelial cells.

Results

The SPARC expression in the tumor epithelia was higher than that in the non-tumorous epithelia in only 5 patients (11%), while negative or weaker SPARC staining in the tumor epithelia was observed in the remaining specimens. SPARC expression level in the CAF was classified into the following 3 categories: 1/3 or less (score 0), 1/3∼2/3 (score 1+), and 2/3 or more (score 2+) of CAF were positive for SPARC [18 patients (38%), 11 (23%), and 18 (38%), respectively]. There was no difference according to clinicopathological characteristics between CAF SPARC level [low (score 0) vs. high (score 1+/2+)]. CAF SPARC level (low vs. high) was not associated with the progression free survival (median, 4.8 vs. 3.0 months; P = 0.259), overall survival (median, 10.2 vs. 8.0 months; P = 0.419), time to treatment failure (median, 4.7 vs. 3.0 months; P = 0.291), and overall response rate (0 vs. 25%; P = 0.850).

Conclusions

SPARC level was not correlated with efficacy of nab-PTX for GC. The results of this exploratory analysis do not support the possibility of SPARC expression level for clinical biomarker regarding nab-PTX in GC.

Clinical trial identification

UMIN Clinical Trials Registry Registration Number: UMIN000012247

Legal entity responsible for the study

Chubu Clinical Oncology Group

Funding

None

Disclosure

Y. Kodera: Honoraria: Olympus, Chugai Pharma, Lilly, Johnson & Johnson, Ajinomoto, Takeda, Yakult Honsha, Taiho Pharmaceutical, Otsuka, Kaken Pharmaceutical, Ono Pharmaceutical, Asahi Kasei, Covidien/Medtronic All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.